Navigation Links
Naltrexone in Medical News

Anti-Craving Drug, Naltrexone Helps Women Quit Smoking

A new study finds that the anti-craving drug, Naltrexone may lessen cessation-related weight gain and negative moods and women who are trying to quit smoking appear //to benefit more than men. As a first step towards individualized medicine, scientists are focusing on gender differences in nicotine...

-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments-

... References to Contrave16 and Contrave48 relate to combinations containing naltrexone SR 16mg or naltrexone SR 48mg, respectively. Trial Design and Results of COR Phase 3 Tr...

Addiction Drug May Help Ease Fibromyalgia

... In small study, naltrexone offered some women relief FRIDAY, Apri...y News) -- Low doses of an inexpensive drug called naltrexone -- already used for years to treat drug addiction ...e drugs." Younger said he got the idea to study naltrexone after hearing that some other doctors had success ...

Suppressing the compulsion to steal

...d randomized them to receive treatment with either naltrexone or placebo. naltrexone is a drug that blocks the effects of endogenous op.... They found that after eight weeks of treatment, naltrexone was able to reduce the urges to steal and stealing...

Drug commonly used for alcoholism, drug addiction, curbs urges of compulsive stealers

...d an eight-week, double-blind study of 25 men and women ages 17-75, who spent an average of at least one hour a week stealing. Those who took the drug naltrexone (mean dose of 117mg/day) reported significantly greater decline in stealing behavior compared to those taking placebo. The research is published in ...

Hormone Drug May Help Drinkers Stay Sober

...humans for the treatment of hyperprolactinemia." Only three medications have FDA approval for treating alcohol dependence -- disulfiram (Antabuse), naltrexone (Depade, ReVia), and acamprosate (Campral). The U.S. National Institutes of Health estimates that almost 18 million people in the United States --...

UCSF Gallo Study Finds Hormone Disorder Drug Could Help Drinkers Stay Sober

...t, according to the National Institutes of Health. But there are just three medications approved to treat alcohol dependence -- disulfiram (Antabuse), naltrexone (Depade, ReVia), and acamprosate (Campral). Lead author of the study is Sebastien Carnicella, PhD, postdoctoral fellow at the Gallo Center. Co-aut...

King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion

...morphine sulfate extended-release with sequestered naltrexone hydrochloride), both of which are designed to resi...morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules ALO-01(morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules (EMBEDA(TM)), Alpharma's p...

Prescribed Meds Still Best Treatment for Alcoholism

...heir relapse rates appeared to be more a function of inadequate exposure to naltrexone and less influenced by CBI," he added. Overall, specialized CBI did not ...ion adherence rates," Zweben said. The findings show that combing MM and naltrexone could benefit a large percentage of alcohol-dependent patients. "Alcohol...

Scientific poster abstracts from the 24th annual meeting of the American Academy of Pain Medicine

... 2005 Treatment Episode Data Set (TEDS) 157 Evaluation of Lacosamide in Diabetic Neuropathic Pain Trials 158 A Pilot Study to Select a Dose of naltrexone Hydrochloride That Will Reduce Subjective Euphoric Effects of Oxycodone Hydrochloride in Non-Dependent, Opioid-Preferring Subjects 159 Tapentadol ...
Naltrexone in Medical Technology

Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)

- Improved Pharmacokinetic Characteristics of Naltrexone SR Associated with Better Tolerability in Clinical Trials - PHOENIX, Oct. 6 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company focused on the treatment of obesity and other ce...

Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting

BRIDGEWATER, N.J., Sept. 9 /PRNewswire-FirstCall/ -- Alpharma Inc. (NYSE: ALO ), a global specialty pharmaceutical company, today announced results from its Phase III pivotal efficacy trial that showed ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochl...

Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session

TAMPA, Fla., May 8 /PRNewswire-FirstCall/ -- Alpharma Inc. (NYSE: ALO ), a global specialty pharmaceutical company, today announced results from clinical trials that showed ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) capsules demonstrated ...

King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use

...rally well tolerated. Evaluation of Plasma naltrexone Concentrations Resulting From Use of ALO-01 (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules for Chronic Pain EMBE...n of morphine sulfate surrounding an inner core of naltrexone hydrochloride. EMBEDA(TM) is intended to treat mo...

Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team

...proof-of-concept Phase 2 trials for OREX-003 (zonisamide and olanzapine to mitigate antipsychotic-associated weight gain) and OREX-004 (fluoxetine and naltrexone to reduce symptoms of obsessive- compulsive disorder) will be discontinued effective immediately. The Company intends to maintain its intellectual pr...

Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule

...besity product candidate, Contrave(R), is a combination of bupropion SR and naltrexone in a proprietary SR formulation that also appears to result in improved tolerability compared to the legacy naltrexone IR formulation. Contrave currently is being studied in four Phase III clini...

Alpharma Presents Positive Pharmacokinetic Study Results of Its Investigational Abuse-Deterrent, Extended-Release Opioid

...stent with a sustained-release formulation and were similar to previous study results for KADIAN(R) (morphine sulfate extended-release) Capsules. Most naltrexone levels were below the assay measurement limits. Adverse events, reported in five subjects, were mild to moderate in intensity and resolved without tre...

Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23

...an Diabetes Association (ADA) in Chicago, IL. Contrave data can be found in category 20B, poster number 45LB entitled, "Weight Loss with Bupropion and naltrexone Improves Markers of Insulin-Resistance." Contrave is a proprietary fixed dose combination of bupropion SR (sustained release) and Orexigen's novel f...
Naltrexone in Biological Technology

Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions

...uated the additional weight loss of Contrave (32mg naltrexone SR/360mg bupropion SR) when added to an intensive ...profile consistent with its individual components, naltrexone and bupropion, two drugs that have been used separ...hich utilized the immediate release formulation of naltrexone as opposed to the proprietary SR formulation used ...

Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings

...yer, M.D., M.P.H., The New York Obesity Research Center, St. Luke's Roosevelt Hospital Center, New York, N.Y. Title: "Combination Therapy with naltrexone + Bupropion Causes Significant Weight Loss and Improves Cardiometabolic Parameters in Obese Individuals: A Randomized Phase 3 Study Over 56 We...

Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results

...t (p<0.001). Contrave was generally well tolerated by patients, with an overall safety profile that was consistent with its individual components, naltrexone and bupropion. The most frequently observed treatment-emergent adverse events for patients on study drug were nausea, headache, constipation and dizz...

Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints

...ea was 4.6%, an improvement over the 11.1% discontinuation rate seen in the Phase 2 trial (NB-201) which utilized the immediate release formulation of naltrexone as opposed to the proprietary SR formulation used in this trial. The most frequently observed treatment-emergent adverse events for patients on study...

Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)

...n patent (U.S. Patent No. 7,375,111) which was issued by the USPTO in May 2008 and broadly covers sustained release (SR) compositions of bupropion and naltrexone combined in a single dosage form. The Weber/Cowley methods patent will provide protection for Contrave through mid 2024. "The issuance of this ...

Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results

...008, which covers SR compositions of bupropion and naltrexone combined in a single dosage form through March 202...ivity. OREX-004 is a proprietary SR formulation of naltrexone plus fluoxetine. The Phase 2a clinical trial, NF- ...xone successfully achieved key objectives (lowered naltrexone Cmax, increased Tmax, comparable AUC). Additionall...

Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting

... 11:00-11:15 a.m. MT Poster Presentation Abstract: 585-P Title: "Relative Bioavailability of Sustained-release (SR) versus Immediate-release (IR) naltrexone (NAL) Formulations in Healthy Obese Volunteers: Implications for Improved Tolerability?" Time: 5:30-7:30 p.m. MT Monday, October 6 Oral Presentat...

New MedPredict Report Suggests Market for Alcoholism Therapies is Underestimated

...rding to this physician panel, there are a number of factors stymieing biopharmaceutical companies, including the lackluster commercial performance of naltrexone and acamprosate, a lack of clear FDA guidance on trial design and resulting indications, the stigma associated with alcoholism and associated corporat...

DNA Predicts Reaction to Drug That Fights Alcohol Dependence

...ing gratification from alcohol. Not only did patients who were treated with naltrexone and have the Asp40 gene variant go without harmful drinking for a longer pe...al without the therapy. Gene variant carriers of all ethnicities who took naltrexone were more likely than their counterparts to have a good clinical result. Ho...
Other Tags
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... By Amy Norton ... -- Yoga has long been believed to improve overall health, ... may also help the heart, a new review finds. ... exercise such as brisk walking, said lead researcher Paula Chu, ... Boston. The review, of 37 clinical trials, found that ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Veretekk.com, Inc. ... JM Ocean Avenue. JM Ocean Avenue has secured ... Veretekk online automated marketing system. JM Ocean Avenue ... 2014 merger of Ocean Avenue and JM International, with ... $2 Billion per year company. , “After nearly 2 ...
(Date:12/15/2014)... 2014 OutMarket , a provider ... Social Media Cheat Sheets ,” a guide that exposes ... results on the top ten social media networks. ... drive awareness, engagement, and customer service. It can also ... an impact on new networks and weather constantly changing ...
(Date:12/15/2014)... The increase in prevalence of disabling hearing loss in the ... contributing to the growth in the global audiological market. Devices ... loss and balance disorders are known as audiological devices. An ... amplifier. The global market is expected to grow at a ... 2014 to 2019. Some of the factors which are driving ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4
(Date:12/10/2014)... 2014 Research and Markets ( ... "Biometrics Market in Japan 2014-2018" report ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of biometrics ... banking and upgradation of the driver,s license is ... market. Besides the aforementioned projects, biometrics is being ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a leader ... million in Series A1 funding led by UK-based Eurovestech. ... participated in the investment round. "We are ... community adopts next-generation sequencing and seeks new approaches for ... Reid Robison , MD MBA, and CEO of Tute ...
(Date:12/3/2014)... Dec. 2, 2014 As part of our ... Technologies is pleased to announce the release of a ... to collect the workforce data that they need. ... been left by existing readers. Many such devices have ... and modern technology. Older models force users to navigate ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Inception Technologies to Release New Biometric Reader 2
Other Contents